Pharsight

Lotemax Sm patents expiration

LOTEMAX SM's oppositions filed in EPO
LOTEMAX SM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534395 BAUSCH AND LOMB INC Ophthalmic suspension composition
Jan, 2036

(11 years from now)

US10596107 BAUSCH AND LOMB INC Ophthalmic suspension composition
Dec, 2036

(12 years from now)

Lotemax Sm is owned by Bausch And Lomb Inc.

Lotemax Sm contains Loteprednol Etabonate.

Lotemax Sm has a total of 2 drug patents out of which 0 drug patents have expired.

Lotemax Sm was authorised for market use on 22 February, 2019.

Lotemax Sm is available in gel;ophthalmic dosage forms.

Lotemax Sm can be used as treatment of post-operative inflammation and pain following ocular surgery.

The generics of Lotemax Sm are possible to be released after 23 December, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Strength (NS) Feb 22, 2022

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 February, 2019

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

How can I launch a generic of LOTEMAX SM before it's drug patent expiration?
More Information on Dosage

LOTEMAX SM family patents

Family Patents